Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Px Ing LLC maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are distributed across 2 distinct examiners and the distinct art units. This distribution indicates that the company's current prosecution is spread across multiple specialized sections of the patent office.
The busiest examiner identified in the data is ROCHELLE, CIERRA MARIE. This examiner is currently handling 1 busiest examiner pending office action. This specific action represents a portion of the total pending office actions for the company. ROCHELLE, CIERRA MARIE is one of the individuals reviewing the company's Biotechnology & Pharmaceuticals applications.
The presence of multiple examiners and art units suggests a varied examination environment. With the pending office actions split between different art units, the company interacts with several reviewers simultaneously. This variety in the Biotechnology & Pharmaceuticals sector means that prosecution outcomes are subject to the review of the distinct examiners and their respective art units. Practitioners should prepare for diverse feedback across these separate office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROCHELLE, CIERRA MARIE | 1 | 100.0% | +0.0% |
| SCHMIDT, IZABELA MARIA | 1 | 65.3% | +42.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18393293 | BIOACTIVE COMPOSITIONS AND METHODS OF USE THEREOF | ROCHELLE, CIERRA MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794729 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | SCHMIDT, IZABELA MARIA | 21d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18393293 | BIOACTIVE COMPOSITIONS AND METHODS OF USE THEREOF | ROCHELLE, CIERRA MARIE | 1627 | §103DP | Non-Final OA | — | Pending | Dec 21, 2023 |
| 17794729 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | SCHMIDT, IZABELA MARIA | 1621 | §103Other | Non-Final OA | 21d | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial